Needham & Company LLC Lowers Autolus Therapeutics (NASDAQ:AUTL) Price Target to $10.00

Autolus Therapeutics (NASDAQ:AUTL) had its price target lowered by equities research analysts at Needham & Company LLC from $11.00 to $10.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock.

Several other equities research analysts have also recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Autolus Therapeutics in a report on Wednesday, October 8th. William Blair reiterated an “outperform” rating on shares of Autolus Therapeutics in a research note on Wednesday, September 24th. Finally, Wall Street Zen downgraded Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 15th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Autolus Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $8.33.

Autolus Therapeutics Price Performance

Autolus Therapeutics stock opened at $1.37 on Monday. Autolus Therapeutics has a one year low of $1.11 and a one year high of $2.70. The business’s fifty day moving average is $1.55 and its 200 day moving average is $1.75. The stock has a market capitalization of $364.61 million, a PE ratio of -1.65 and a beta of 2.01.

Autolus Therapeutics (NASDAQ:AUTL) last issued its earnings results on Wednesday, November 12th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.07). The business had revenue of $21.19 million during the quarter, compared to analysts’ expectations of $21.08 million. Autolus Therapeutics had a negative return on equity of 63.76% and a negative net margin of 439.69%. As a group, sell-side analysts expect that Autolus Therapeutics will post -0.94 EPS for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

A number of hedge funds have recently modified their holdings of AUTL. Armistice Capital LLC lifted its holdings in Autolus Therapeutics by 9.1% during the second quarter. Armistice Capital LLC now owns 12,000,000 shares of the company’s stock valued at $27,360,000 after purchasing an additional 1,000,000 shares in the last quarter. TFG Asset Management GP Ltd lifted its stake in shares of Autolus Therapeutics by 10.5% during the 2nd quarter. TFG Asset Management GP Ltd now owns 9,500,000 shares of the company’s stock valued at $21,660,000 after buying an additional 900,000 shares in the last quarter. Cetera Investment Advisers boosted its holdings in Autolus Therapeutics by 17.6% in the 2nd quarter. Cetera Investment Advisers now owns 617,172 shares of the company’s stock worth $1,407,000 after buying an additional 92,300 shares during the period. Atle Fund Management AB increased its stake in Autolus Therapeutics by 130.5% in the 2nd quarter. Atle Fund Management AB now owns 1,105,461 shares of the company’s stock worth $2,520,000 after buying an additional 625,817 shares in the last quarter. Finally, R Squared Ltd bought a new stake in Autolus Therapeutics during the second quarter valued at about $50,000. Institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.